´ËÏÂ¥±¥¢¥Á¡¼¥àÊؤê

´ËÏÂ¥±¥¢¥Á¡¼¥àÊؤê

2017ǯ

2017/12/7
´ËÏÂ¥±¥¢Êؤꡡ12·î¹æ

Âè8²ó ¾ëÀ¾´ËÏÂ¥±¥¢¹Ö±é²ñ¡ÁÌÀÆü¤«¤éÌòΩ¤Ä´ËÏ°åÎÅ¡ª¡ª¡Á¤¬¡¢10·î26Æü¡ÊÌڡ˸á¸å6»þ30ʬ¤è¤ê¿·½É½»Í§¥¹¥«¥¤¥ë¡¼¥à¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£

¡Ø´ËÏ°åÎÅ Up To Date¡Ù¤Ç¡¢Åìµþ½÷»Ò°å²ÊÂç³Øɱ¡ ÌôºÞÉô¤ÎÄÍÀîËãÍø»ÒÀèÀ¸¤Ë¤´¹Ö±é¤¤¤¿¤À¤­¤Þ¤·¤¿¡£
WHOÊý¼°¤¬¤óáÖÄ˼£ÎÅË¡¤Î»°Ãʳ¬½üÄË¥é¥À¡¼¤Ç¤Ï¡¢·ÚÅÙ¡ÁÃæÅùÅÙ¤ÎÄˤߤˤϼ奪¥Ô¥ª¥¤¥ÉÄÃÄËÌô¡ÊStep­¶ opioid¡Ë¡¢ÃæÅùÅÙ¡Á¹âÅÙ¤ÎÄˤߤˤÏÍѤ¤¤ë¶¯¥ª¥Ô¥ª¥¤¥ÉÄÃÄËÌô¡ÊStep­· opioid¡Ë¤òÍѤ¤¤ë¤è¤¦¿ä¾©¤·¤Æ¤¤¤Þ¤¹¡£ºÇ¶á¤Ï¡¢ÌôºÞÁªÂò»è¤¬Áý¤¨¡¢¡ÖÃæÅùÅ١פΤ¬¤ó¤Ë¤è¤ëÄˤߤËÂФ·¤Æ¡¢¤É¤Î¥ª¥Ô¥ª¥¤¥ÉÄÃÄËÌô¤ò»ÈÍѤ·¤¿¤é¤è¤¤¤Î¤«Çº¤à¾ìÌ̤⿤¯¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£¤³¤Î¹Ö±é¤Ç¤Ï¡¢¡ÖÃæÅùÅ١פΤ¬¤ó¤Ë¤è¤ëÄˤߤËÂФ·¤Æ¡¢Step­· opioid¤«¤éƳÆþ¤¹¤ëºÝ¤ÎÍ­¸úÀ­¤äǦÍÆÀ­¡¢Step­¶opioid¤Ç¤ÎƳÆþ¤ò¸¡Æ¤¤¹¤ë¤Î¤Ï¤É¤Î¤è¤¦¤Ê¾ì¹ç¤«¡¢2016ǯ¤ÎÏÀʸ¢¨¤Ê¤É¤òÄ󼨤·¤Ä¤Äʬ¤«¤ê¤ä¤¹¤¯²òÀ⤷¤Æ¤¯¤À¤µ¤¤¤Þ¤·¤¿¡£
¢¨ Elena Bandieri, et al: Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 34: 436-442, 2016

¤Þ¤¿¡¢º£²ó¤ÎÆÃÊֱ̹é¤Ç¤Ï¡¢ºë¶Ì°å²ÊÂç³Ø¹ñºÝ°åÎÅ¥»¥ó¥¿¡¼ Àº¿À¼ðáç²Ê ¶µ¼ø¤ÎÂçÀ¾½¨¼ùÀèÀ¸¤Ë¡Ø´ËÏ°åÎŤÇÃΤäƤª¤¯¤Ù¤­Àº¿À¾É¾õ¤È¤½¤ÎÂбþ¡Ù¤Ë¤Ä¤¤¤Æ¤´¹Ö±é¤¤¤¿¤À¤­¤Þ¤·¤¿¡£
¤¬¤ó´µ¼Ô¤µ¤ó¤ÎÃæ¤Ë¤Ï¡¢¤½¤Î·Ð²áÃæ¤ËÀº¿À¾É¾õ¤ÇǺ¤àÊý¤â¤¤¤Þ¤¹¡£Àº¿À¾É¾õ¤Ï¤´ËÜ¿Í¡¦¤´²È²¤Ë¤È¤Ã¤Æ¶ìÄˤǤ¢¤ê¡¢°Õ»×·èÄ꺤Æñ¡¢Æþ±¡´ü´Ö¤Î±äĹ¡¢¼«»¦Î¨¤Î¾å¾º¤Ë´ØÍ¿¤¹¤ë¤È¤â¤¤¤ï¤ì¡¢Å¬ÀÚ¤ËÂбþ¤¹¤ë¤³¤È¤¬É¬ÍפǤ¹¡£º£²ó¤Î¹Ö±é¤Ç¤Ï¡¢¼ç¤ÊÀº¿À¾É¾õ¤È¤·¤Æ¡¢¤¦¤ÄÉ¡¦¤»¤óÌѤˤĤ¤¤Æ²òÀ⤷¤Æ¤¤¤¿¤À¤­¤Þ¤·¤¿¡£
·ñÂÕ´¶¡¢¿©ÍßÉÔ¿¶¤Ê¤É¤Ï¿ÈÂξɾõ¤È»×¤¤¹þ¤ß¤¬¤Á¤Ç¤¹¤¬¡¢¤¦¤ÄɤβÄǽÀ­¤âµ¿¤¦É¬Íפ¬¤¢¤ë¤³¤È¡¢ÌôʪÎÅË¡¤äÀº¿ÀÎÅË¡¤Ë¤Ä¤¤¤Æ¤â¤ªÏ䬤¢¤ê¤Þ¤·¤¿¡£
¤»¤óÌѤϵÞÀ­Ç¾µ¡Ç½ÉÔÁ´¤Î¾õÂ֤Ȥ¤¤¨¤Þ¤¹¡£·ò˺¡¢¼º¸«Åö¡¢½¸Ã溤Æñ¤Ê¤É¤¬¤¢¤ë¤È¤­¡¢¤»¤óÌѤòµ¿¤Ã¤Æ¿Ç»¡¤·¤Þ¤¹¡£¸¶°ø¤Ë¤Ï¡¢Ç¾¼«ÂΤÎÌäÂê¤Î¤Û¤«¡¢Ç¾°Ê³°¤ÎÌäÂê¡¢ÌôºÞ¤Ê¤É¤Ë¤è¤ë±Æ¶Á¤¬¤¢¤ê¤¨¤Þ¤¹¡£Ä¹´ü´Ö¿©»öÎ̤¬¸º¾¯¤·¡¢¥Ó¥¿¥ß¥óB1¤¬·ç˳¤·¤¿¤³¤È¤Ç¥¦¥§¥ë¥Ë¥Ã¥±Ç¾¾É¤È¤Ê¤ê¡¢¤»¤óÌѤò¤­¤¿¤·¤¿´µ¼Ô¤µ¤ó¤ÎÎã¤Ë¤Ä¤¤¤Æ¤â¤´¾Ò²ð¤¤¤¿¤À¤­¤Þ¤·¤¿¡£Î×¾²·¿¤Ë¤Ï²á³èÆ°·¿¡¢Äã³èÆ°·¿¡¢º®¹ç·¿¤¬¤¢¤ê¤Þ¤¹¤¬¡¢Äã³èÆ°·¿¤Ï¸«Íî¤È¤µ¤ì¤ä¤¹¤¤¤Î¤ÇÃí°Õ¤¬É¬ÍפǤ¹¡£¸¶°ø¤ÎƱÄê¤È½üµî¡¢ÊݸŪ¼£ÎÅ¡¢ÂоÉÎÅË¡¤È¤·¤Æ¤ÎÌôʪÎÅË¡¤Ë¤Ä¤¤¤Æ²òÀ⤷¤Æ¤¤¤¿¤À¤­¤Þ¤·¤¿¡£
¹Ö±é¤ÎºÇ¸å¤Ë¤Ï¡¢ÂçÀ¾ÀèÀ¸¤¬¤³¤ì¤Þ¤Ç¤Ë½Ð²ñ¤Ã¤¿´µ¼Ô¤µ¤ó¤Î¥¨¥Ô¥½¡¼¥É¤È¶¦¤Ë¡¢´µ¼Ô¤µ¤ó¤Î¿´Åª³°½ý¸åÀ®Ä¹¤Ë¤Ä¤¤¤Æ¡¢²È²¤Î¶ìǺ¤Ï¶¯¤¤¤¬¼Ò²ñŪ»Ù±ç¤Ï¾¯¤Ê¤¯²È²¥±¥¢¤¬É¬Íפʤ³¤È¤Ë¤Ä¤¤¤Æ¡¢¤´²È²¤¬Ë´¤¯¤Ê¤Ã¤¿¸å¤Î°ä²¥±¥¢¤â½ÅÍפʤ³¤È¤Ë¤Ä¤¤¤Æ¤ªÏä·¤¯¤À¤µ¤ê¡¢»ä¤¿¤Á¤Î»Ù¤¨¤äÌÜɸ¤È¤â¤Ê¤ë¤è¤¦¤Ê²¹¤«¤¤¥á¥Ã¥»¡¼¥¸¤ò¤¤¤¿¤À¤­¤Þ¤·¤¿¡£

ʸɮ¡§ÂíÌî ÍۻҡʷıþµÁ½ÎÂç³Øɱ¡ ´ËÏÂ¥±¥¢¥»¥ó¥¿¡¼¡Ë

¡ã¡ãÁ°¹æ¤Ø ¼¡¹æ¤Ø¡ä¡ä

¥Ú¡¼¥¸¤ÎÀèƬ¤Ø